期刊
RESPIRATORY MEDICINE
卷 218, 期 -, 页码 -出版社
W B SAUNDERS CO LTD
DOI: 10.1016/j.rmed.2023.107414
关键词
Asthma; Comorbidities; Biologics; Type 2 inflammation; Biomarkers; Asthma management
The development of monoclonal antibody therapies has revolutionized the treatment of severe asthma by targeting specific pathways and has provided further understanding of the heterogeneity of the disease. However, the availability of multiple agents requires practical guidance for specialists to make informed treatment choices for patients with severe asthma.
The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. We also focus on the role of biomarkers and treatable traits, including comorbidities, in the choice of asthma biologics, highlight which treatments have been demonstrated to be steroid sparing in corticosteroid dependent asthma, and provide practical guidance that can drive shared decision making on treatment choice with patients. In addition, we summarize what is known to date regarding long-term safety of these drugs, and lastly, discuss future directions in biologics research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据